JP7406253B2 - 免疫回避性ベクターおよび遺伝子療法のための使用 - Google Patents
免疫回避性ベクターおよび遺伝子療法のための使用 Download PDFInfo
- Publication number
- JP7406253B2 JP7406253B2 JP2020538958A JP2020538958A JP7406253B2 JP 7406253 B2 JP7406253 B2 JP 7406253B2 JP 2020538958 A JP2020538958 A JP 2020538958A JP 2020538958 A JP2020538958 A JP 2020538958A JP 7406253 B2 JP7406253 B2 JP 7406253B2
- Authority
- JP
- Japan
- Prior art keywords
- aav
- enveloped
- vector
- virus
- envelope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims description 231
- 238000001415 gene therapy Methods 0.000 title description 18
- 238000000034 method Methods 0.000 claims description 244
- 210000004027 cell Anatomy 0.000 claims description 226
- 150000007523 nucleic acids Chemical class 0.000 claims description 170
- 102000039446 nucleic acids Human genes 0.000 claims description 164
- 108020004707 nucleic acids Proteins 0.000 claims description 164
- 108700019146 Transgenes Proteins 0.000 claims description 123
- 241000700605 Viruses Species 0.000 claims description 122
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 120
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 117
- 239000002245 particle Substances 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 102
- 230000003612 virological effect Effects 0.000 claims description 100
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 201000010099 disease Diseases 0.000 claims description 64
- 238000004519 manufacturing process Methods 0.000 claims description 63
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 62
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 61
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 61
- 230000008685 targeting Effects 0.000 claims description 56
- 208000035475 disorder Diseases 0.000 claims description 52
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 47
- 239000000232 Lipid Bilayer Substances 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 41
- 230000001225 therapeutic effect Effects 0.000 claims description 39
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 33
- 210000000234 capsid Anatomy 0.000 claims description 31
- 239000012528 membrane Substances 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 210000001808 exosome Anatomy 0.000 claims description 30
- 239000013607 AAV vector Substances 0.000 claims description 27
- 108010076282 Factor IX Proteins 0.000 claims description 27
- 229960004222 factor ix Drugs 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims description 23
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 23
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 22
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 22
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 21
- 102000004128 Myotubularin Human genes 0.000 claims description 20
- 108090000697 Myotubularin Proteins 0.000 claims description 20
- 208000009429 hemophilia B Diseases 0.000 claims description 20
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 19
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 18
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 18
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 18
- 208000009292 Hemophilia A Diseases 0.000 claims description 18
- 238000010362 genome editing Methods 0.000 claims description 17
- 230000005847 immunogenicity Effects 0.000 claims description 17
- 102000057593 human F8 Human genes 0.000 claims description 14
- 229960000027 human factor ix Drugs 0.000 claims description 14
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 14
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 13
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 13
- 241000702421 Dependoparvovirus Species 0.000 claims description 13
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 12
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 12
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 12
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 12
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 12
- 206010003694 Atrophy Diseases 0.000 claims description 12
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 12
- 102100021947 Survival motor neuron protein Human genes 0.000 claims description 12
- 101710171779 Survival motor neuron protein Proteins 0.000 claims description 12
- 230000037444 atrophy Effects 0.000 claims description 12
- 208000021642 Muscular disease Diseases 0.000 claims description 11
- 201000009623 Myopathy Diseases 0.000 claims description 11
- 201000011252 Phenylketonuria Diseases 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 11
- 229960000900 human factor viii Drugs 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 10
- 108020005544 Antisense RNA Proteins 0.000 claims description 10
- 201000011297 Citrullinemia Diseases 0.000 claims description 10
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 10
- 102000001690 Factor VIII Human genes 0.000 claims description 10
- 108010054218 Factor VIII Proteins 0.000 claims description 10
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 10
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 10
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims description 10
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 10
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 10
- 108020004459 Small interfering RNA Proteins 0.000 claims description 10
- 208000016617 citrullinemia type I Diseases 0.000 claims description 10
- 239000003184 complementary RNA Substances 0.000 claims description 10
- 229960000301 factor viii Drugs 0.000 claims description 10
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 10
- 108091070501 miRNA Proteins 0.000 claims description 10
- 239000002679 microRNA Substances 0.000 claims description 10
- 208000007056 sickle cell anemia Diseases 0.000 claims description 10
- 239000002924 silencing RNA Substances 0.000 claims description 10
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- 102000053640 Argininosuccinate synthases Human genes 0.000 claims description 9
- 108700024106 Argininosuccinate synthases Proteins 0.000 claims description 9
- 208000024720 Fabry Disease Diseases 0.000 claims description 9
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 9
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 9
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 claims description 9
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims description 9
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 9
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 claims description 9
- 101710106576 NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 claims description 9
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims description 9
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims description 9
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 9
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 9
- 208000003571 choroideremia Diseases 0.000 claims description 9
- 230000007812 deficiency Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 8
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 8
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 8
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 8
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 8
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 7
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 6
- 208000005980 beta thalassemia Diseases 0.000 claims description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- 108010054126 retinoid isomerohydrolase Proteins 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 7
- 230000006698 induction Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 description 239
- 230000001506 immunosuppresive effect Effects 0.000 description 132
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 114
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 94
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 94
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 94
- 230000006870 function Effects 0.000 description 92
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 71
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 71
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 71
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 66
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 64
- 239000012642 immune effector Substances 0.000 description 48
- 229940121354 immunomodulator Drugs 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 38
- 241000700584 Simplexvirus Species 0.000 description 30
- 150000001413 amino acids Chemical group 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 18
- 239000012636 effector Substances 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- -1 huntingtin Proteins 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 241000713800 Feline immunodeficiency virus Species 0.000 description 12
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 241000713311 Simian immunodeficiency virus Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 9
- 102100031351 Galectin-9 Human genes 0.000 description 9
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 9
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 9
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 9
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 9
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 9
- 101000620777 Homo sapiens Rab proteins geranylgeranyltransferase component A 1 Proteins 0.000 description 9
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 9
- 102000017578 LAG3 Human genes 0.000 description 9
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 102100029740 Poliovirus receptor Human genes 0.000 description 9
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 description 9
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 9
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 9
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 9
- 230000005745 host immune response Effects 0.000 description 9
- 230000003308 immunostimulating effect Effects 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 108010048507 poliovirus receptor Proteins 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 8
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108700004026 gag Genes Proteins 0.000 description 8
- 101150098622 gag gene Proteins 0.000 description 8
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 7
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 208000024556 Mendelian disease Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229940126546 immune checkpoint molecule Drugs 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 5
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 5
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 5
- 102100037904 CD9 antigen Human genes 0.000 description 5
- 101150026402 DBP gene Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 101150008036 UL29 gene Proteins 0.000 description 5
- 101150011902 UL52 gene Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 108700004029 pol Genes Proteins 0.000 description 5
- 101150088264 pol gene Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 4
- 206010043391 Thalassaemia beta Diseases 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 108700004025 env Genes Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 244000309711 non-enveloped viruses Species 0.000 description 3
- 150000008298 phosphoramidates Chemical class 0.000 description 3
- 239000013644 scAAV2 vector Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102100026292 Asialoglycoprotein receptor 1 Human genes 0.000 description 2
- 101710200897 Asialoglycoprotein receptor 1 Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 229960003697 abatacept Drugs 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 102000043321 human CTLA4 Human genes 0.000 description 2
- 102000051631 human SERPINA1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150005393 CBF1 gene Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101100066069 Homo sapiens F8 gene Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000037977 Immune checkpoint ligands Human genes 0.000 description 1
- 108091008029 Immune checkpoint ligands Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 1
- 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000645321 Mus musculus Titin Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108700030796 Tsg101 Proteins 0.000 description 1
- 101150072717 Tsg101 gene Proteins 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 101150059443 cas12a gene Proteins 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- 102000010660 flotillin Human genes 0.000 description 1
- 108060000864 flotillin Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
- C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146391A JP2023160938A (ja) | 2018-01-11 | 2023-09-08 | 免疫回避性ベクターおよび遺伝子療法のための使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616167P | 2018-01-11 | 2018-01-11 | |
| US62/616,167 | 2018-01-11 | ||
| US201862768779P | 2018-11-16 | 2018-11-16 | |
| US62/768,779 | 2018-11-16 | ||
| PCT/US2019/013361 WO2019140311A1 (en) | 2018-01-11 | 2019-01-11 | Immuno-evasive vectors and use for gene therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146391A Division JP2023160938A (ja) | 2018-01-11 | 2023-09-08 | 免疫回避性ベクターおよび遺伝子療法のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510522A JP2021510522A (ja) | 2021-04-30 |
| JP2021510522A5 JP2021510522A5 (https=) | 2022-02-07 |
| JP7406253B2 true JP7406253B2 (ja) | 2023-12-27 |
Family
ID=65444323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538958A Active JP7406253B2 (ja) | 2018-01-11 | 2019-01-11 | 免疫回避性ベクターおよび遺伝子療法のための使用 |
| JP2023146391A Pending JP2023160938A (ja) | 2018-01-11 | 2023-09-08 | 免疫回避性ベクターおよび遺伝子療法のための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146391A Pending JP2023160938A (ja) | 2018-01-11 | 2023-09-08 | 免疫回避性ベクターおよび遺伝子療法のための使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200338216A1 (https=) |
| EP (1) | EP3737768A1 (https=) |
| JP (2) | JP7406253B2 (https=) |
| KR (1) | KR20200128519A (https=) |
| CN (1) | CN111836896A (https=) |
| AU (1) | AU2019206639A1 (https=) |
| BR (1) | BR112020014093A2 (https=) |
| CA (1) | CA3088897A1 (https=) |
| CL (1) | CL2020001850A1 (https=) |
| IL (1) | IL275951A (https=) |
| MX (1) | MX2020007390A (https=) |
| RU (1) | RU2020126574A (https=) |
| SG (1) | SG11202006298XA (https=) |
| WO (1) | WO2019140311A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4118219A4 (en) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Novel use of aspirin compound in increasing nucleic acid expression |
| US20230355803A1 (en) * | 2020-06-24 | 2023-11-09 | Chameleon Biosciences, Inc. | Extracellular vesicles with immune modulators |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| WO2023028035A1 (en) * | 2021-08-23 | 2023-03-02 | University Of Florida Research Foundation, Incorporated | Lipid enveloped recombinant aav particles for gene therapy use |
| EP4660308A1 (en) * | 2023-01-31 | 2025-12-10 | Synplogen Co., Ltd. | Helper gene |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001512142A (ja) | 1997-07-31 | 2001-08-21 | カイロン コーポレイション | 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法 |
| JP2002514388A (ja) | 1998-04-29 | 2002-05-21 | ユニバーシティー・オブ・サウザーン・カリフォルニア | 修飾エンベロープエスコート蛋白質を含むレトロウイルスベクター |
| JP2002518050A (ja) | 1998-06-19 | 2002-06-25 | メディジーン・アクチェンゲゼルシャフト | Ａａｖの構造タンパク質、その製造及び用途 |
| WO2006138670A2 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| JP2008504821A (ja) | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| US20160067228A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4691611B1 (ja) | 2010-01-15 | 2011-06-01 | 富士フイルム株式会社 | 有機電界発光素子 |
| WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
| CN104887717B (zh) * | 2015-06-04 | 2019-05-31 | 爱康得生物医学技术（苏州）有限公司 | 一种免疫增强试剂 |
| WO2017136764A1 (en) * | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
-
2019
- 2019-01-11 BR BR112020014093-7A patent/BR112020014093A2/pt not_active IP Right Cessation
- 2019-01-11 EP EP19705841.5A patent/EP3737768A1/en not_active Withdrawn
- 2019-01-11 AU AU2019206639A patent/AU2019206639A1/en not_active Abandoned
- 2019-01-11 CA CA3088897A patent/CA3088897A1/en active Pending
- 2019-01-11 CN CN201980018276.3A patent/CN111836896A/zh active Pending
- 2019-01-11 RU RU2020126574A patent/RU2020126574A/ru unknown
- 2019-01-11 WO PCT/US2019/013361 patent/WO2019140311A1/en not_active Ceased
- 2019-01-11 JP JP2020538958A patent/JP7406253B2/ja active Active
- 2019-01-11 KR KR1020207022774A patent/KR20200128519A/ko not_active Ceased
- 2019-01-11 SG SG11202006298XA patent/SG11202006298XA/en unknown
- 2019-01-11 US US16/961,500 patent/US20200338216A1/en not_active Abandoned
- 2019-01-11 MX MX2020007390A patent/MX2020007390A/es unknown
-
2020
- 2020-07-09 IL IL275951A patent/IL275951A/en unknown
- 2020-07-10 CL CL2020001850A patent/CL2020001850A1/es unknown
-
2023
- 2023-09-08 JP JP2023146391A patent/JP2023160938A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001512142A (ja) | 1997-07-31 | 2001-08-21 | カイロン コーポレイション | 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法 |
| JP2002514388A (ja) | 1998-04-29 | 2002-05-21 | ユニバーシティー・オブ・サウザーン・カリフォルニア | 修飾エンベロープエスコート蛋白質を含むレトロウイルスベクター |
| JP2002518050A (ja) | 1998-06-19 | 2002-06-25 | メディジーン・アクチェンゲゼルシャフト | Ａａｖの構造タンパク質、その製造及び用途 |
| JP2008504821A (ja) | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| WO2006138670A2 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| US20160067228A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector immune responses |
Non-Patent Citations (1)
| Title |
|---|
| www.moleculartherapy.org, 2012年，vol.20 no.5，p.960-971，doi:10.1038/mt.2011.303 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128519A (ko) | 2020-11-13 |
| US20200338216A1 (en) | 2020-10-29 |
| JP2021510522A (ja) | 2021-04-30 |
| WO2019140311A1 (en) | 2019-07-18 |
| BR112020014093A2 (pt) | 2020-12-01 |
| EP3737768A1 (en) | 2020-11-18 |
| MX2020007390A (es) | 2020-10-14 |
| AU2019206639A1 (en) | 2020-08-20 |
| CA3088897A1 (en) | 2019-07-18 |
| IL275951A (en) | 2020-08-31 |
| JP2023160938A (ja) | 2023-11-02 |
| CL2020001850A1 (es) | 2020-12-04 |
| SG11202006298XA (en) | 2020-07-29 |
| RU2020126574A (ru) | 2022-02-11 |
| CN111836896A (zh) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200502B2 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| JP7406253B2 (ja) | 免疫回避性ベクターおよび遺伝子療法のための使用 | |
| JP7756439B2 (ja) | 異種間適合性アデノ随伴ウイルス組成物およびその使用方法 | |
| US20230355803A1 (en) | Extracellular vesicles with immune modulators | |
| WO2023201274A1 (en) | Use of an irak4 modulator for gene therapy | |
| JP2021510522A5 (https=) | ||
| CA3219160A1 (en) | Genomic safe harbors | |
| CN117642173A (zh) | 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒 | |
| US20250242018A1 (en) | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration | |
| Reul | Viral gene transfer systems for cancer immunotherapy: semireplication-competent VSV and receptor-targeted AAV for the delivery of immunomodulatory proteins | |
| Li | Optimization of Adeno-associated Virus Vectors Encoding Immune Checkpoint Protein for Arthritis Gene Therapy | |
| Mason | SRSF1-mediated gene therapy as a therapeutic approach for C9ORF72-related amyotrophic lateral sclerosis and fronto-temporal dementia (ALS-FTD) | |
| HK40049414A (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| Reul | Viral gene transfer systems for cancer immunotherapy | |
| CN115803438A (zh) | 用于cd3+细胞体外和体内表达基因治疗产物的启动子序列 | |
| HK1240977B (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| HK1240977A1 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230322 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230908 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230925 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7406253 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |